Zai Lab Ltd
Zai Lab Ltd (ZLAB): 5 pipeline candidates · 2 upcoming catalysts · ~188 mo cash runway · 8 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
187.8 months
D/E 0.66 · 0% dilution
Lead: Phase 3
5 candidates
2 upcoming, next in ~590d
1 buy · 29 sells (180d)
A transparent, data-derived signal for Zai Lab Ltdacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.0B
Cash
$651.3M
Quarterly Burn
$11.9M
Runway
187.8 mo
Revenue
$99.6M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
96
Total value held
$487.8M
| Holder | Shares | Value |
|---|---|---|
| rtw investments, lp | 6,574,032 | $123.7M |
| ra capital management, l.p. | 5,707,262 | $107.4M |
| citadel advisors llc | 1,721,832 | $32.4M |
| bamco inc /ny/ | 1,658,318 | $31.2M |
| adar1 capital management, llc | 1,425,367 | $26.8M |
| fmr llc | 1,262,391 | $23.7M |
| blackrock, inc. | 865,146 | $16.3M |
| rock springs capital management lp | 814,707 | $15.3M |
| ubs group ag | 504,191 | $9.5M |
| jane street group, llc | 466,926 | $8.8M |
Showing top 10 of 96 institutional holders of Zai Lab Ltd. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Zai Lab Ltd's pipeline?
Zai Lab Ltd (ZLAB) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Zai Lab Ltd's lead drug candidate?
Zai Lab Ltd's most advanced tracked candidate is zl-1109 (Phase 3) for Thyroid Eye Disease (TED).
What is Zai Lab Ltd's next catalyst?
Zai Lab Ltd's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Multicenter, Double-blinded, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy" — expected January 29, 2028.
What is Zai Lab Ltd's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Zai Lab Ltd has approximately 187.8 months of cash runway.
What is Zai Lab Ltd's market capitalization?
Zai Lab Ltd's market capitalization is approximately $2.0B.
Get the full picture on Zai Lab Ltd
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.